Sino Biopharmaceutical Total Liabilities

Sino Biopharmaceutical (SBHMY) currently reports a total liabilities of $37B as of June 2026. That compares with $29B in the prior-year period — up 26.9% year over year. Use the charts on this page to explore Sino Biopharmaceutical's total liabilities history and peer comparisons.

Sino Biopharmaceutical's total liabilities increased from $29B to $37B — a 26.9% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sino Biopharmaceutical reported $37B in total liabilities as of June 2026. That compares with $29B in the prior-year period — up 26.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $37B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Sino Biopharmaceutical, and consider following SBHMY for alerts when major investors trade the stock.

Sino Biopharmaceutical is classified in the Healthcare sector. On total liabilities, it currently shows $37B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SBHMY with unrelated industries.